The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 21, 2016

Filed:

Aug. 07, 2013
Applicants:

Irbm—science Park S.p.a., Pomezia (RM), IT;

C.n.c.c.s. Scarl Collezione Nazionale Dei Composti Chimici E Centro Screening, Pomezia (RM), IT;

Inventors:

Sergio Altamura, Pomezia, IT;

Alberto Bresciani, Pomezia, IT;

Giulia Breveglieri, Ferrara, IT;

Danilo Fabbrini, Pomezia, IT;

Roberto Gambari, Ferrara, IT;

Steven Harper, Pomezia, IT;

Ralph Laufer, Pomezia, IT;

Edith Monteagudo, Pomezia, IT;

Emanuela Nizi, Pomezia, IT;

Paola Pace, Pomezia, IT;

Vincenzo Summa, Pomezia, IT;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 263/32 (2006.01); A61K 31/421 (2006.01); C07D 413/14 (2006.01); C07D 413/12 (2006.01); C07D 417/12 (2006.01); C07D 417/14 (2006.01); A61K 31/422 (2006.01); A61K 31/427 (2006.01); A61K 31/4439 (2006.01); A61K 31/454 (2006.01); A61K 31/4709 (2006.01); A61K 31/496 (2006.01);
U.S. Cl.
CPC ...
C07D 263/32 (2013.01); A61K 31/421 (2013.01); A61K 31/422 (2013.01); A61K 31/427 (2013.01); A61K 31/4439 (2013.01); A61K 31/454 (2013.01); A61K 31/4709 (2013.01); A61K 31/496 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01); C07D 417/14 (2013.01);
Abstract

The present invention relates to compounds of formula (I) and (IV), and pharmaceutically acceptable salts, tautomers, stereoisomers thereof, which are inhibitors of histone deacetylase (HDAC). The compounds of the present invention are for use in the treatment of disorders that are ameliorated by inhibition of HDAC such as cancer and hemoglobinopathies like β-thalassemia or sickle cell anemia.


Find Patent Forward Citations

Loading…